Tetrahydrobiopterin (H 4 -biopterin) is an essential cofactor of a set of enzymes that are of central metabolic importance, i.e. the hydroxylases of the three aromatic amino acids phenylalanine, tyrosine, and tryptophan, of ether lipid oxidase, and of the three nitric oxide synthase (NOS) isoenzymes. As a consequence, H 4 -biopterin plays a key role in a vast number of biological processes and pathological states associated with neurotransmitter formation, vasorelaxation, and immune response. In mammals, its biosynthesis is controlled by hormones, cytokines and certain immune stimuli. This review aims to summarize recent developments concerning regulation of H 4 -biopterin biosynthetic and regulatory enzymes and pharmacological effects of H 4 -biopterin in various conditions, e.g. endothelial dysfunction or apoptosis of neuronal cells. Also, approaches towards gene therapy of diseases like the different forms of phenylketonuria or of Parkinson's disease are reviewed. Additional emphasis is given to H 4 -biopterin biosynthesis and function in nonmammalian species such as fruit fly, zebra fish, fungi, slime molds, the bacterium Nocardia as well as to the parasitic protozoan genus of Leishmania that is not capable of pteridine biosynthesis but has evolved a sophisticated salvage network for scavenging various pteridine compounds, notably folate and biopterin.
.153] (SR). One important role of H
-biopterin is its well studied function for hydroxylating aromatic amino acids by phenylalanine, tyrosine and tryptophan hydroxylases thus being essential for the formation of the neurotransmitters dopamine, noradrenaline, adrenaline and serotonin. In addition, it serves as a cofactor for glyceryl-ether monooxygenase [EC 1.14.16.5]. As a result from activating oxygen for catalysis of these reactions, H 4 -biopterin is converted to 4a-hydroxy-H 4 -biopterin from which it is regenerated by two additional enzymes, i.e. pterin-4a-carbinolamine dehydratase [EC 4.2.1.96] and dihydropteridine reductase [EC1. 6.99.7] (DHPR). The protein sequence of pterin-4a-carbinolamine dehydratase (PCD) is identical to that of the transcription factor dimerization cofactor of hepatocyte nuclear factor 1 α (DCoH). For this reason, PCD is usually termed PCD/DcoH [1, 2] . A scheme of H 4 -biopterin biosynthesis and regeneration is shown in Fig. (1) .
Several of the H 4 -biopterin synthesizing and recycling enzymes have been cloned and their genomic and protein crystal structures were revealed within the last few years. This allowed elucidation of the reaction mechanism and stereochemistry of H 4 -biopterin de novo biosynthesis and *Address correspondence to this author at the Institute of Medical Chemistry and Biochemistry, University of Innsbruck, Fritz-Pregl-Strasse 3, A-6020 Innsbruck, Austria; Tel: ++43-512-507-3518; Fax: ++43-512-507-2865; E-mail: gabriele.werner-felmayer@uibk.ac.at recycling. The recent review by Thöny and collegues [3] comprehensively summarizes the present knowledge on several aspects of H 4 -biopterin biosynthesis and regeneration as well as cofactor and cellular functions of H 4 -biopterin with special regard to H 4 -biopterin deficiency and its significance for hyperphenylalaninaemia and neurological diseases. The cofactor role of H 4 -biopterin for all three NOS isoenzymes is still not conclusively revealed but recent evidence clearly shows that it catalytically participates in the electron transfer to the heme/oxygen complex. This process involves Hδ3-biopterin radical formation which seems to be uniquely found for NOS. A detailed survey of the new developments in this field can be found in this issue (Gorren and Mayer, Tetrahydrobiopterin in nitric oxide synthesis: a novel biological role for pteridines).
Here, recent findings concerning regulation of H 4 -biopterin biosynthesis not yet covered in [3] as well as pharmacological effects of H 4 -biopterin as revealed by various pathological conditions such as endothelial dysfunction or neurodegeneration will be reviewed. Recent approaches towards gene therapy of atypical phenylketonuria or Parkinson's disease are summarized. Furthermore, we shall also refer to novel data concerning H 4 -biopterin and its significance for development and differentiation in mammals and non-mammalian species.
REGULATION OF H 4 -BIOPTERIN BIOSYNTHESIS

GTP-CHI
In general, in the major sites of aromatic amino acid hydroxylation, i.e. the liver and the central nervous system, all three H 4 -biopterin biosynthetic enzymes are constitutively expressed. The first indication that H 4 -biopterin levels are increased due to up-regulation of GTP-CHI expression came from experiments in the rat where treatment with reserpine, a neuroleptic drug which causes catecholamine depletion, or with insulin, induced a cycloheximide-sensitive increase of GTP-CHI activity in adrenal cortex and medulla and hence increased H 4 -biopterin levels [4, 5] . Recently, it was shown for mouse brain endothelial cells that insulin-induced GTP-CHI expression involves signalling via the phosphatidylinositol-3-kinase pathway [6] . Another early observation was that immune activation causes increased excretion of neopterin, which originates from 7,8-dihydroneopterin triphosphate, the first intermediate of H 4 -biopterin biosynthesis (Fig. 1) . Since then the biochemical basis for pteridine biosynthesis induced during immune activation and in response to hormones and other stimuli emerged from a large body of experimental data (reviewed in [7] ). Here, we briefly summarize and up-date our current understanding (Fig. 2) .
A panel of different human and rodent cell lines respond to various immune stimuli with increasing intracellular levels of H 4 -biopterin and, in the case of human cells, release of varying amounts of 7,8-dihydroneopterin/neopterin (Fig. 1) . The list summarized in [7] can be extended for the human keratinocyte cell line HaCaT [8] and mouse osteoblastic cells [9] . This increase is caused by an up to two orders of magnitude induction of GTP-CHI mRNA and protein expression. Major stimuli (a detailed list can be found in [7] ) for this induction are pro-inflammatory cytokines like interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IFN-α, IFN-β or bacterial cell wall components like lipopolysaccharide (LPS) or lipoteichoic acid (LTA). In addition, also certain hormones (e.g. follicle stimulating hormone), growth factors (e.g. epithelial growth factor (EGF) or neuronal growth factor (NGF)), cAMP (all reviewed in [7] ), vasoactive intestinal peptide (VIP) [10] and the vasodilatory peptide adrenomedullin [11] induce GTP-CHI expression. A recent study with primary bovine adrenal medullary cells showed that long-term Ca 2+ -influx upregulated GTP-CHI gene expression [12] . Anti-inflammatory cytokines like IL-4, IL-10, transforming growth factor-β (TGF-β), drugs like dexamethasone or cyclosporin A (reviewed in [7] ) or, as was shown for catecholaminergic neurons, the neurohormone melatonin [13] down-regulate GTP-CHI expression. The quintessence from these data is that virtually all cell types are able to synthesize H 4 -biopterin either constitutively (e.g. liver and neuronal cells) and/or in response to a large variety of stimuli that induce GTP-CHI expression (shown on mRNA and protein expression levels for different mammalian cell types in e.g. [8, 10, 11, 14, 15] ). In vivo, GTP-CHI expression is increased in various organs upon treatment with LPS [16] [17] [18] . Fig. (2) . Transcriptional regulators of GTP-CHI expression in various cell types (for a detailed list see [7] .
Although transcriptional regulation of GTP-CHI is a wellknown fact, data concerning regulation of the promoter of GCH1, the GTP-CHI encoding gene, are still limited. 5'-regulatory regions from the mouse (~620 bp [19] and 681 bp [20] , respectively), human (2628 bp [21] ) and, more recently, from the rat (5812 bp [22] ) gene were identified. A comparison of the 681-bp core promoter from wild-type and hph-1 mice, a GTP-CHI deficient mutant, showed that the hph-1 mutation does not affect this genomic region and identified some elements presumably involved in basal transcription [20] . In a more detailed study, basal and cAMP response elements from the rat gene were identified within the 142 bp GC-rich sequence upstream from the transcription start site highly conserved also in mouse and human GCH1 [22] . However, so far no elements regulating the response to IFN-γ or stimuli other than cAMP could be functionally verified [21] . Experiments with pyrrolidine dithiocarbamate (PDTC), an inhibitor of IκB release, and with curcumin, an inhibitor of AP-1 binding, suggested that cooperation of NFκB and AP-1 was essential for cytokine-induced GTP-CHI in mouse osteoblastic cells [9] . In vascular smooth muscle cells and in cardiac myocytes from rat, PDTC prevented GTP-CHI mRNA expression in response to LPS and IL-1β/IFN-γ, respectively [23, 24] . Involvement of NFκB is also indirectly suggested by experiments with cycloheximide which caused superinduction of GTP-CHI activity in murine fibroblasts treated with IFN-γ/TNF-α, a phenomenon not observed in human fibroblasts or THP-1 myelomonocytes [25] . Cycloheximide also "superinduced" GTP-CHI mRNA levels in rat vascular smooth muscle cells treated with IFN-γ/LPS [26] and in human HaCaT keratinocytes treated with IL-1β/IFN-γ [8] . In contrast, as is shown in a more recent study done in rat C6 glioma cells, PDTC and SN-50, a more specific NFκB inhibitor, had no effect on TNF-α-induced GTP-CHI mRNA expression [27] . Several data indicate that the promoter activity of the GTP-CHI gene is complex and may be regulated cell specifically. It will also be interesting to see which factors determine whether a cell type expresses GTP-CHI constitutively at high levels or only in response to certain stimuli. More detailed experiments using reporter-promoter analysis and mutagenesis of putative transcription factor binding sites are required for understanding induction of GTP-CHI mRNA expression by cytokines and other stimuli.
GTP-CHI mRNA is an extensively spliced transcript. In 1992, isolation of two alternatively spliced GTP-CHI mRNA variants from human liver was described [28] . We could recently identify two more alternatively spliced GTP-CHI variants and could show that levels of all GTP-CHI mRNA transcripts are strongly induced by treatment with IFN-γ/TNF-α in human monocytoid cells (THP-1) and in human dermal fibroblasts whereas their levels are only slightly affected in cells with constitutive GTP-CHI expression, i.e. neuroblastoma (SK-N-SH) and hepatoma (Hep-G2) cells [15] . In both SK-N-SH and Hep-G2, other IFN-γ-inducible genes are expressed, e.g. the T-cell chemoattractant CXCL11 [29] . Thus, these cell lines are not defective in IFN-γ signalling but rather have different means for promoter control than THP-1 cells or fibroblasts. Three of the four GTP-CHI mRNA variants are spliced at the boundary of exons 5 and 6 encoding C-terminally truncated proteins that are not catalytically active and may be rapidly degraded within the cell [15, 30, 31] . The fourth mRNA variant is spliced within exon 6 without affecting the reading frame [15] . Alternative splicing of GTP-CHI is not restricted to humans but was also found for the primitive eukaryote Physarum polycephalum as well as for Drosophila melanogaster. In Physarum, splicing occurs at a position homologous to that observed in humans, i.e. the 3'-most boundary which is the boundary of exons 6 and 7 and corresponds to the boundary of exons 5 and 6 in humans, resulting in C-terminal truncation [15] . In contrast, splicing of GTP-CHI mRNA observed in Drosophila affects the Nterminus and occurs due to different transcription start sites [32] . It is unclear whether 5'-splicing also occurs in other species than Drosophila or, vice versa, whether splicing at the C-terminus can also be found in Drosophila. Moreover, it remains to be seen whether the multiple 3'-splice variants result from erroneous splicing or whether the proteins they encode could intercalate into decameric GTP-CHI thus disturbing enzyme activity. A hint in this direction comes from a patient suffering from DOPA-responsive dystonia who expressed a GTP-CHI splice variant lacking exon 5 and part of exon 6. In this patient, mRNA expression of fulllength and alternatively spliced GTP-CHI correlated with GTP-CHI activity [33] , and co-expression of wild-type and truncated GTP-CHI in COS-7 cells impaired enzyme activity [34] . However, the view that such a mechanism was the basis of DOPA-responsive dystonia is not generally accepted since 40 % of these patients have no mutation within the reading frame of GTP-CHI [35] .
In addition to transcriptional regulation, GTP-CHI is also regulated by post-translational mechanisms such as Nterminal cleavage and phosphorylation (reviewed in [3] ). In contrast to bacterial GTP-CHI, rat liver GTP-CHI contains high-affinity calcium-binding sites and mutation of these sites led to a marked loss of enzyme activity [36] . Further regulators of GTP-CHI activity are GTP (reviewed in [37] ), H 4 -biopterin and other reduced pteridines, and phenylalanine. Phenylalanine and H 4 -biopterin excert their effect via GTP-CHI feed-back regulatory protein (GFRP), a pentameric protein purified from rat liver which mediates feed-back inhibition of GTP-CHI by H 4 -biopterin and feedforward stimulation of the enzyme by phenylalanine [38, 39] . Two pentameric GFRP molecules form a protein complex with one decameric GTP-CHI molecule [40] to which H 4 -biopterin and phenylalanine bind via residues from both proteins and with different affinity [41] . GFRP mRNA is abundant in rat liver and kidney but can also be detected in heart, brain, lung, testis and at very low levels also in spleen and muscle [38] . A detailed survey of GFRP and GTP-CHI mRNA expression in rat brain, pineal and adrenal glands showed that the two genes are not generally co-expressede.g. in pineal and adrenal glands GFRP expression lackedand that they may be differentially regulated in tissues that express both transcripts [42] . In the brain, GFRP mRNA was abundant in serotonin neurons but was not detected in dopamine neurons. Accordingly, phenylalanine stimulated H 4 -biopterin synthesis in serotonin neurons but not in dopamine neurons. However, feed-back inhibition of GTP-CHI by H 4 -biopterin was observed in both types of neurons. The fact that phenylalanine could reverse this feed-back inhibition only in serotonin but not in dopamine neurons suggests that in certain cell types H 4 -biopterin may directly affect GTP-CHI or involve a not yet identified GFRP-like protein [42] . GFRP is not restricted to liver and neuronal tissues but was also detected in rat vascular smooth muscle cells where GFRP mRNA is constitutively expressed and is increased about twofold by IFN-γ but not by LPS [43] . Also in this cell type, phenylalanine stimulates GTP-CHI activity and reverses feed-back inhibition by H 4 -biopterin and it was shown that this regulation is mediated by GFRP [43] . We recently found that this regulatory mechanism is also operative in human THP-1 myelomonocytoma cells. Notably, IFN-γ and other pro-inflammatory cytokines had no effect whereas LPS drastically down-regulated GFRP expression thus uncoupling pteridine synthesis from phenylalanine concentrations and from feed-back inhibition by reduced pteridines. We also found LPS-mediated downregulation of GFRP mRNA expression in human umbilical vein endothelial cells as well as in various tissues from LPStreated rats [43a] . Uninhibited production of H 4 -biopterin could contribute to pathological NO production during infections with Gram-negative bacteria and sepsis. This speculation is substantia-ted by recent findings with hemoperfusion over polymyxin B fibers in patients with septic shock and in animal models. Removal of H 4 -biopterin by unexpected binding of the cofactor to polymyxin fibers essentially contributed to the rapid increase of blood pressure after hemoperfusion [44] .
PTPS and SR
Both PTPS and SR are constitutively expressed enzymes and are targets for phosphorylation. The respective genes have been characterized from different species (for a more detailed review see [3] ). In human cells, and especially in monocytes/macrophages which have a characteristically low PTPS activity, this enzyme becomes rate-limiting for H 4 -biopterin biosynthesis when GTP-CHI expression is induced by cytokines [25, 45] . As a result, 7,8-dihydroneopterin triphosphate accumulates and is cleaved by phosphatases to 7,8-dihydroneopterin/neopterin (see Fig. 1 ) [45] . The low PTPS activity of human cells in general and especially of monocytes/macrophages is not caused by impaired transcription of the PTS gene but by skipping of the 23 bp long exon 3 which leads to a premature stop. Applying realtime PCR, we could show that the ratio of full-length PTPS mRNA to exon-3-lacking transcript directly correlated with PTPS activity of the respective cell type. Exon-3-lacking PTPS mRNA was detectable in several tested human cell types, even in those which predominantly produced H 4 -biopterin and only little neopterin such as fibroblasts. In contrast, exon-3-lacking PTPS mRNA was not detectable in mouse cells which show an about 100-fold higher enzyme activity than human cells (K.Leitner et al., manuscript in preparation). The molecular basis for this species-specific difference in PTPS activity is not yet clarified. In contrast to PTPS, SR is abundant in several tested human and murine cell types and SR activity exceeds PTPS activity up to two orders of magnitude [25, 45] .
H 4 -BIOPTERIN DEFICIENCIES AND GENE THERAPY
Deficient production of H 4 -biopterin is associated with various diseases, most prominently and well documented with a special variant of hyperphenylalaninaemia which is unresponsive to low-phenylalanine diet. This so-called "atypical" phenylketonuria can be caused by mutations in several enzymes of H 4 -biopterin biosynthesis or recycling. In addition, H 4 -biopterin deficiencies without hyperphenylalaninaemia, namely DOPA-responsive dystonia caused by GTP-CHI deficiency and a central nervous system-localized DHPR deficiency, are known (reviewed in [3, 46] , and by H. Shintaku, Inborn metabolic disorders due to tetrahydrobiopterin deficiency and their treatment, this issue; more information on H 4 -biopterin deficiencies and clinical data is available from http://www.bh4.org/). Moreover, H 4 -biopterin levels are decreased in a number of neurological diseases (reviewed in [3] ) and recently also cases of classical phenylketonuria who responded to H 4 -biopterin supplementation were reported [47] .
Diseases associated with deficient production of H 4 -biopterin are potential targets for gene therapy and first steps towards this aim have already been made. It was recently shown that primary fibroblasts from PTPS deficient patients could produce and efficiently release H 4 -biopterin when transduced with GTP-CHI and PTPS in triple-cistronic retroviral vectors. Such engineered cells may thus be used as depository cells for cofactor supply to various organs [48] . Moreover, overexpression of GTP-CHI could also be useful for treatment of classical phenylketonuria. In general, these patients have sufficient cofactor but cannot adequately clear phenylalanine due to a genetic defect of phenylalanine hydroxylase. Besides phenylalanine hydroxylase gene transfer to liver tissue, one strategy could be to remove circulating phenylalanine by enabling any heterologous tissue for phenylalanine hydroxylation thus functioning as a "metabolic sink" that prevents formation of toxic phenylalanine metabolites. Transducing only phenylalanine hydroxylase to those tissues like muscle [49] or T cells [50] required exogenous H 4 -biopterin supplementation. Recent work showed that primary human epidermal keratinocytes co-transduced with phenylalanine hydroxylase and GTP-CHI for sufficient H 4 -biopterin production efficiently hydroxylated phenylalanine [51] . Similar approaches have been proposed for the gene therapy of cardiovascular and neurological disease associated with H 4 -biopterin-dependent enzymes. To prevent intimal hyperplasia caused by impaired NO production, vein grafts co-transduced with NOS2 (inducible NOS) and GTP-CHI were engineered that produced maximal NO levels persisting for more than 10 days [52] . No such cotransduction strategy has yet been attempted for transducing NOS1 (neuronal NOS) or NOS3 (endothelial NOS) to human vascular smooth muscle and human endothelial cells, respectively [53, 54] . However, also in this case cotransduction with GTP-CHI might be beneficial since NOS3 expressed by human endothelial cells at physiological levels is not saturated with H 4 -biopterin [55] . This was also observed in superficial veins where IL-1 β-induced GTP-CHI and hence increased H 4 -biopterin levels caused activation of NOS3 without concomitant induction of NOS2 [56] . Accordingly, as was shown for NOS1 over-expression in human vascular smooth muscle cells, addition of sepiapterin which is intracellularly converted into H 4 -biopterin enhanced NOS activity in transduced cells [53] . Also, various attempts for achieving local continuous L-DOPA production in the striatum as a strategy to cure Parkinson's disease have been reported. Again, H 4 -biopterin had to be supplied either directly or its synthesis had to be ensured by over-expression of GTP-CHI parallel to transduction with tyrosine hydroxylase [57] [58] [59] . As was shown recently in a rat model of Parkinson's disease, triple transduction with adenoassociated virus vectors expressing tyrosine hydroxylase, aromatic L-amino acid decarboxylase and GTP-CHI resulted in long-term behavioural recovery [60] . Interestingly, as was shown for Drosophila, tyrosine hydroxylase and GTP-CHI are co-immunoprecipitated with anti-GTP-CHI antibodies. This finding and the observation that addition of H 4 -biopterin could not fully restore tyrosine hydroxylase activity in GTP-CHI mutants suggested that physical association of tyrosine hydroxylase with GTP-CHI may be required for optimal regulation [61] . For gene therapy involving H 4 -biopterin-dependent enzymes, co-transduction of GTP-CHI might therefore yield superior results over exogenous H 4 -biopterin supply. With regard to this it also notable that exogenously supplied H 4 -biopterin is cytotoxic to catecholaminergic cell lines whereas elevation of intracellular H 4 -biopterin levels had no such effect [62] .
PHARMACOLOGICAL EFFECTS OF H 4 -BIOPTERIN
Numerous pharmacological effects of H 4 -biopterin have been observed ( Table 1 ) and many of them can be related to the multifaceted biological functions of H 4 -biopterindependent enzymes, especially NOS. That intracellular H 4 -biopterin levels are limiting for activity of H 4 -biopterindependent enzymes has been recognized for catecholamine biosynthesis several decades ago [63, 64] and was shown also for all NOS isoenzymes in a large variety of cells from different species (reviewed in [7] ). This is also observed in vivo and it was shown in hph-1 mice that peripheral administration of H 4 -biopterin led to elevated brain H 4 -biopterin levels and increased NOS activity [65] . Important features in this respect are that NOS1 and NOS3, albeit to a much lower extent than NOS1, do not only produce NO but also reactive oxygen intermediates (ROI) and peroxynitrite when subsaturated with H 4 -biopterin and that H 4 -biopterin itself non-enzymatically generates superoxide during autoxidation [66] . In addition, peroxynitrite oxidizes H 4 -biopterin to quinonoid 5,6-dihydrobiopterin which is converted to 7,8-dihydropterin by losing its side chain [67] . On the other hand, H 4 -biopterin like other reduced pterins can scavenge reactive oxygen species (for further review see this issue, Oettl and Reibnegger, Pteridine derivatives as modulators of oxidative stress). Two further observations illustrate the complexity of the field: H 4 -biopterin bound to alpha-melanocyte stimulating hormone is stable to oxidation by either molecular oxygen or UVB light [68] and hydrogen peroxide inactivates PCD/DCoH thus interfering with H 4 -biopterin recycling, a process which is thought to be causative for development of the depigmentation disorder vitiligo [69] . These are just some examples indicating that various parameters influence the availability of fully reduced cofactor which is particularly important in connection with NOS since several products from NOS, i.e. either NO formed under optimal conditions or ROI formed under suboptimal conditions as well as peroxynitrite which is formed in any condition of parallel NO and ROI formation can influence the final outcome. During recent years oxidative stress turned out to be a common theme of a variety of pathological states including neurodegenerative diseases and vascular dysfunction. The interplay of NO and ROI is therefore of particular interest with respect to these pathological conditions which are often associated with immune activation (for recent reviews on the significance of NO in this respect see [70] [71] [72] [73] ). In the following, we shall focus on the experimental data which integrate H 4 -biopterin into this complex network where it seems to play a multifaceted role.
H 4 -Biopterin effects on Cell Survival
Not surprisingly, both H 4 -biopterin and NO can act either as cytoprotective or as cytotoxic agents but not all H 4 -biopterin effects can be linked to its cofactor role or its influence on a test system's oxidative status ( Table 1) . Several experiments with PC12 cells demonstrate how the decision whether a cell proliferates or dies, either due to apoptosis or necrosis, is influenced by the interplay of H 4 -biopterin, NO and ROI but also by effects of H 4 -biopterin unrelated to NO and ROI formation. Intracellularly elevated H 4 -biopterin in cells treated with sepiapterin which is converted into the active cofactor within the cell [74] directly influenced cell cycle progression via expression of Mycrelated proteins [75] . This mechanism increased cell proliferation as long as trophic support by e.g. nerve growth factor or serum was supplied but enhanced apoptosis upon withdrawal of this trophic support [75] . In contrast, extracellular addition of H 4 -biopterin prevented PC12 cells from apoptosis induced by deprivation of trophic support. This effect of H 4 -biopterin was attributed to activation of Ca 2+ -channels and the cAMP/protein kinase A pathway rather than to its cofactor activity or autooxidation. In these experiments, H 4 -biopterin had no effect on PC12 differentiation but only enhanced cell survival. Furthermore, NO-induced cell death of PC12 cells was prevented by exogenous H 4 -biopterin, an effect which is suggested to be caused by degradation of NO in the course of autooxidation of H 4 -biopterin (for a more detailed review of several of these data see [76] ). A similar effect, but of increasing intracellular H 4 -biopterin levels, was observed in the mouse osteoblastic cell line MC3T3-E1 where this treatment prevented cytokine-induced apoptosis, an effect which involved NO formation [77] . When added extracellularly to growing undifferentiated PC12 cells but also to other catecholamine-synthesizing cell lines, namely SK-N-BE(2)C and CATH.a, H 4 -biopterin was cytotoxic, an effect which was not observed with non-catecholaminergic cell types. This cytotoxicity was not seen with 7,8-dihydrobiopterin or oxidized biopterin and also was not observed when intracellular H 4 -biopterin levels were elevated by sepiapterin treatment [62] . The cytotoxicity of H 4 -biopterin involved formation of ROI as was indicated by the beneficial effect of enzymes detoxifying ROI and by thiol agents [62] . Reduced pteridine-species (di-hydro and tetra-hydro derivatives of neopterin, biopterin and folate) also directly induced apoptosis in undifferentiated and differentiated human neuronal NT2/HNT cells and also this effect involved formation of ROI [78] . NT2/HNT apopotosis ROI formation [78] brain (mouse) neuronal injury during transient ischemia NOS activation caspase-3 [80] dopaminergic neurons cytoprotection in glutathione depletion antioxidant [81] mouse osteoblasts prevents cytokine-induced NO-mediated apoptosis unknown [77] precontracted rat aortae, vasodilation and restoration of endothelial dysfunction NOS activation [82] canine cerebral arteries, [83] murine pial arterioles, [84] porcine arterioles after ischemia/reperfusion injury, [85] humans with hypercholesterolemia, [86] spontaneously hypertensive rats, [87] thoracic aortae from atherosclerotic mice, [88] human and pig atherosclerotic coronary arterioles, [89] human saphenous veins from patients with bypass operations, [90] human arteries from patients with coronary artery disease, [91] chronic smokers, [92, 93] rats with ischemic acute renal failure, [94] humans with diabetes, [95] hph-1 mouse aortae, [96] pigs with lung transplantation, [97] arotae from insulin-resistant rats [98] human endothelial cells inhibition of platelet aggregation NOS activation [103] rabbit platelets anti-aggregating activity of endothelial cells ↓ ROI formation [103] bovine aortic endo-thelial cells angiogenesis ↑ unknown [104] rat brain, PC12 neurotransmitter release ↑ Ca
2+
-channel/PKA [76] rat cardiac myocytes arginine transport ↑ CAT-2 mRNA ↑ [105] haemopoietic cell lines proliferation unknown [106, 107] skin melanin biosynthesis ↓ tyrosinase inhibition [108] Extracellular H 4 -biopterin may physiologically occur in the brain. As was shown for CATH.a catecholaminergic cells and primary bovine adrenal medullary cells, substantial amounts of H 4 -biopterin can be released from these neurons [62] . It was also shown that rat brain synaptosomes, PC12 cells and control or dopamine neuron depleted rat striatum take up exogenous H 4 -biopterin by passive diffusion [79] . Notably, immune-histochemical and in situ hybridization studies of several rat brain areas, the pineal and adrenal gland revealed that GTP-CHI immunoreactivity was restricted to monoaminergic neurons but could not be found in NOS1 neurons [80] . Moreover, H 4 -biopterin producing neurons were located close to NOS1 neurons which supports the hypothesis that these neurons take up H 4 -biopterin. Alternatively, H 4 -biopterin may also stem from the circulation or cells could take up 7,8-dihydroneopterin triphosphate, the product from GTP-CHI which is then converted into H 4 -biopterin within NOS1 neurons which have been shown to express SR [80] . After neuronal injury by transient forebrain ischemia, NO-mediated cell death can be observed and it was shown that reduction of available H 4 -biopterin by inhibiting GTP-CHI also reduced NOS activity as well as caspase-3 gene expression and neuronal injury [80] . On the other hand, increasing intracellular levels of H 4 -biopterin prevented dopaminergic neurons from toxicity induced by glutathione depletion, one of the earliest events observed in Parkinson's disease [81] .
The following conclusions can be drawn from several of these sometimes opposing data: (i) effects of intracellular elevation of H 4 -biopterin levels are often different from those observed with increasing extracellular levels; (ii) H 4 -biopterin, and more generally, reduced pterins, are involved in apoptotic and necrotic cell death induced by various conditions but can also be cytoprotective; (iii) depending on the experimental system, cofactor activity, autooxidation, and interaction with ROI and possibly other reactive species such as various radicals may account for the effects of H 4 -biopterin; and (iv) additional H 4 -biopterin effects not related to these mechanisms, namely interference with cell cycle progression or stimulation of Ca 2+ -channels, may interact.
H 4 -Biopterin and Vascular Dysfunction
The complex interactions of NO, ROI and H 4 -biopterin also influence the proper function of vasculature and many pathological conditions caused by vascular dysfunction can be attributed to an imbalance in this system. Here, several studies consistently show that H 4 -biopterin is beneficial for endothelial function and that this effect is caused by its cofactor role for NOS and hence reduction of ROI formation [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] . That the H 4 -biopterin effects are NOS-specific was unambiguously shown at least in one in vivo study: in chronic smokers only H 4 -biopterin but not H 4 -neopterin, which cannot support NOS activity, could improve endothelium-dependent vasodilation [93] . Notably, ascorbic acid, which has well established beneficial vascular effects (reviewed in [99] ), increased intracellular H 4 -biopterin levels of porcine and human endothelial cells thus allowing for optimal NOS activity [99] [100] [101] . This effect of ascorbic acid was caused by chemical stabilization of H 4 -biopterin rather than by effects on H 4 -biopterin biosynthesis [100] and seems to be independent of the ability of vitamin C to scavenge superoxide anions [101] . For the vascular system, H 4 -biopterin seems to be an undisputed benefactor. As compared to the neuronal system, one major difference is of course that NOS is the only H 4 -biopterin-dependent enzyme in blood vessels which facilitates interpretation of results. Also, endothelial cells may be less vulnerable to oxidative stress in terms of cell survival than neurons. In addition, serum provides a much better buffer system for reduced compounds than CSF which has only little protein content so that it is conceivable that H 4 -biopterin is better protected from autoxidation and readily taken up as fully reduced pterin by endothelial cells when applied to the circulation. One recent study with respect to endothelial cells reported that exogenous H 4 -biopterin triggered superoxide anion production of platelets which scavenged endothelial cell-derived NO and thus inhibited the NO-mediated anti-aggregating activity of indomethacintreated endothelial cells [103] . In the absence of platelets, H 4 -biopterin served simply as NOS cofactor for endothelial cells [103] . The mechanism by which H 4 -biopterin could stimulate platelet NAD(P)H oxidase, however, remains elusive and further work will be necessary to clarify whether this mechanism is operative in vivo. Another report showed that H 4 -biopterin stimulated formation of tube-like structures in bovine endothelial cells and this angiogenic effect was inhibited by the SR inhibitor N-acetylserotonin [104] .
Further H 4 -Biopterin Effects
In rat striatum and PC12 cells, H 4 -biopterin was shown to stimulate dopamine release which was caused by activation of Ca 2+ -channels and the cAMP/protein kinase A pathway. In addition, stimulation of release of various neurotransmitters from different brain regions was observed (reviewed in [76] ). Recent work provides evidence that H 4 -biopterin augments arginine transport in rat cardiac myocytes by upregulating mRNA expression of cationic amino acid transporter CAT-2 and that LPS-induced arginine transport strictly depended on presence of extracellular H 4 -biopterin [105] . Growth-promoting effects of exogenous H 4 -biopterin were not only observed in PC12 cells but also in heamopoietic cell lines [106, 107] . And finally, a role for H 4 -biopterin in the skin as inhibitor of tyrosinase thus interfering with melanin biosynthesis was reported several years ago [108] . In these studies, the molecular mechanism of the H 4 -biopterin effect is not clear and it will be interesting to get further insight. Fig. (3) summarizes a simplified scheme of pteridine formation from GTP.
H 4 -BIOPTERIN IN PRIMITIVE EUKARYOTES AND BACTERIA
Notably, not all organisms use SR for conversion of 6-pyruvoyl-H 4 -pterin into H 4 -biopterin: in the lemon mutant of the silkworm Bombyx mori an enzyme that consists of two carbonyl transferases is responsible for this step [110] .
For a limited number of organisms, namely the fungi Neurospora crassa, Phycomyces blakesleeanus, the flagellated algae Euglena gracilis, and the acellular slime mold Physarum polycephalum, coexistence of both pathways was shown [111, 112] . For the cellular slime mold Dictyostelium discoideum in contrast, folate is a vitamin [113] and this organism does not synthesize H 4 -biopterin but its isomer dictyopterin (6-(D-threo-1',2'-dihydroxypropyl) pterin) [29] . Also dictyopterin is formed from GTP via GTP-CHI and it was suggested that isomerization is either linked to the reduction of 6-pyruvoyl-H 4 -pterin or is caused by epimerisation of H 4 -biopterin [114] .The recent characterization of Dictyostelium SR shows that the enzyme has genuine SR activity producing H 4 -biopterin from 6-pyruvoyltetrahydropterin [115] thus making epimerisation of H 4 -biopterin the most likely source for dictyopterin. This isomer does not support mammalian NOS1 [112] and no data are available whether it may support other H 4 -biopterindependent reactions. Rather, it was shown that dictyopterin but also H 4 -biopterin inhibited G protein activation and it was proposed that this was caused by inhibiting GDP-GTP exchange [116] .
In Physarum polycephalum, NOS was purified and cloned [112, 117] and we could recently also clone and characterize DPHR from this organism and show phenylalanine hydroxylase activity. Physarum DHPR shares 44 % amino acid identity with human DHPR and showed a remarkable selectivity for pterin substrates with a C1' hydroxy group (C. Wild, G. Golderer, P. Gröbner, G. Werner-Felmayer, E.R. Werner, submitted). Thus, in Physarum, H 4 -biopterin serves cofactor functions similar to mammalian cells. More details on regulation and biological significance of H 4 -biopterin/NO biosynthesis in Physarum are outlined below (see H 4 -biopterin in development and differentiation). Also in Phycomyces, H 4 -biopterin functions as cofactor for NOS which is involved in sporulation (see below) [118] and the presence of phenylalanine hydroxylase as well as possibly other aromatic amino acid hydroxylases is likely.
One of the few prokaryotes reported to express H 4 -biopterin biosynthetic activities is Nocardia sp., a bacterium with NOS activity and the ability to form cGMP [119] . Most   Fig. (3) . Simplified scheme of pteridine synthesis in different organisms.
Nocardiae are free-living saprophytes but some species are opportunistic pathogens in humans and other animals. It would be interesting to see whether several of Nocardia sp. behave similar with respect to H 4 -biopterin/NO/cGMP biosynthesis and whether this pathway plays a role in pathogenesis of norcardiosis. Furthermore, one could also speculate that this pathway is involved in formation of the typical substrate mycelium which readily breaks into rods and coccoid elements or in production of conidia which some Nocardiae produce (see below for involvement of this pathway in sporulation). So far, it was not investigated whether Nocardia also synthesizes folate.
In different species of cyanobacteria but also in some photosynthetic bacteria and the archaebacterium Sulfolobus solfataricus, pteridine glycosides consisting of unconjucated pteridines and various sugars are known (for more details see [120] ). The function of these compounds is still not clarified but in Oscillatoria sp the biopterin glucoside was induced by UV-A radiation and it was suggested that this compound protects the cyanobacterium from adverse effects of UV-A radiation [121] . In Syncechococcus sp. PCC 7942, the pterin moiety of this glucoside is H 4 -biopterin which is conjugated to UDP-glucose by a recently identified UDP-glucose: H 4 -biopterin glucosyltransferase [120] . For this organism, it was recently found that the H 4 -biopterin-glucoside complex is required for normal cell growth (Choi, YK Pteridine metabolism of the parasitic protozoan Leishmania illustrates the fascinating effectiveness of parasitic evolution. Though being pteridine auxotroph, this genus does not produce either pteridine but has developed sophisticated mechanisms for taking up and reducing biopterin and folate. These include biopterin and folate transporters BT1 and FT1, pteridine reductase PTR1, and dihydrofolate-thymidylate synthase (DHFR-TS). In contrast to folate transporters which are well characterized also from other species, BT1 is the only known example of an unconjugated pteridine transporter. Furthermore, PTR1 is a novel type of pteridine reductase which sequentially reduces oxidized biopterin to the dihydro-and tetrahydro-derivative. This enzyme is structurally unrelated to DHFR and can also reduce folate. In parallel, this organism also expresses DHFR which usually carries out the reduction of folate to its tetrahydro-derivative but can be by-passed by PTR1, an effective means for the parasite to overcome anti-folate chemotherapy. It was shown that this pteridine salvage is expressed throughout the infectious cycle of various pathogenic Leishmania species (reviewed in [122] ). Recently, also DHPR which reduces quinonoid 6,7 [8] dihydrobiopterin and exists in parallel to PTR1 was characterized from Leishmania. This work showed that Leishmania DHPR is biochemically similar to DHPR from other species. Interestingly, Leishmania DHPR is encoded by a multi-copy gene with 8 to 9 copies arranged in a head-totail manner which might cause transcriptional amplification (Lye LF, Cunningham, ML, Beverley, SM, Identification and characterization of quinonoid dihydropteridine reductase from Leishmania major, 12 th International Symposium of Chemistry and Biology of Pteridines and Folates, Bethesda, USA, June 17-22, 2001 ). Evidence for the importance of H 4 -biopterin for this organism is also provided by studies on over-expression of BT1 and PTR1. In vitro cultured Leishmania cells increase their efficiency for utilizing biopterin due to over-expression of BT1 and PTR1 [123] . Sequencing of the Leishmania major Friedlin genome is underway and revealed that the genes of this organism are organized into large polycistronic clusters of adjacent genes. It was shown that BT1 resides together with other genes in such a cluster termed LD1 and that overexpression of BT1 was beneficial for growth whereas BT1 knock-out mutants showed slower growth and a significant reduction of infectivity for macrophages. Immunization of mice with recombinant BT1 resulted in reduction of parasite burden (reviewed in [124] ). In a very recent report it was shown that H 4 -biopterin is critical for differentiation of Leishmania [125] (for more details see below). The biochemical functions of H 4 -biopterin in this parasite, however, are not yet clear. It was suggested that H 4 -biopterin is involved in oxidant resistance of Leishmania [122] . On the other hand, NOS with NOS1 characteristics was purified from Leishmania donovani [126] . The role of NOS for protozoan parasites -NOS-like activities were reported for Plasmodium falciparum [127] where the enzyme activity was Ca 2+ -independent and for Trypanosoma cruzi [128] where the enzyme showed NOS1-like characteristics and also soluble guanylate cyclase and NMDA-like receptors were expressed [128] -has not yet been clarified and killing of various of these parasites by NO formed by the host's NOS2 is a much better established issue. One could speculate, however, that the parasite's NOS may be involved in invading or persisting in host cells by influencing e.g. gene expression of the host or that endogenous NO/cGMP signalling is required for the developmental cycle of the parasite. Recently, it was suggested for Trypanosoma cruzi , that the parasite's NOS is involved in motility of epimastigotes [129] . Since also the infectious cycle of Leishmania includes mobile and stationary stages this could also play a role here.
H 4 -BIOPTERIN IN DEVELOPMENT AND DIFFER-ENTIATION
Systematic studies on biosynthesis of H 4 -biopterin during development and differentiation are still rare. Work using in vitro cultures of embryonic rat mesencephalon and hypothalamus without glial support cells monitored the development of dopamine neurons and established that H 4 -biopterin is primarily localized in dopamine neurons. H 4 -biopterin levels increased 6-fold in mesencephalon and 20-fold in hypothalamus within the 21 days of in vitro organ culture [130] . During Drosophila adult development, DOPA and in the following also other catecholamines increased around 50 min after adult ecdysis and paralleled pigmentation and hardening of the adult cuticle. Using mutants defective in either aromatic amino acid hydroxylases or H 4 -biopterin biosynthesis it was established that H 4 -biopterin, phenylalanine and tyrosine hydroxylase are essential for proper development [131] .
Expression of PCD/DCoH, the 4a-hydroxy-H 4 -pterin dehydratase/transcription coactivator of hepatic nuclear factor 1, was followed during human fetal development [132] , in rat egg and embryogenesis [133] and in Xenopus over-expressing this protein [134] . In fetal liver, PCD/DCoH was detectable as early as 6.7 weeks of gestation and it reached 31 % of the adult value at 17.3 weeks. DHPR expression was strictly correlated to PCD/DCoH and 33 % of adult H 4 -biopterin levels were expressed in fetal liver [132] . In the rat egg and during embryogenesis, PCD/DCoH might function in tissue specific gene expression mediated by HNF1 but seems to serve also HNF1-independent functions in the eyes (pigmented epithelium) and the brain (ependym cells) [133] . The overexpression of PCD/DCoH in Xenopus eggs induced formation of ectopic pigment cells in the epidermis and it was proposed that PCD/DCoH is not only essential for melanin biosynthesis but also a regulator for the differentiation of pigment producing cells [134] . The molecular basis for such a regulation and how far this effect can be attributed to H 4 -biopterin requires further investigation. After all, studies on H 4 -biopterin levels and biosynthesis in human hair follicle cells and during the synchronized murine hair cycle suggest such a not yet defined role of H 4 -biopterin which seems to extend its effect on melanin biosynthesis [135] .
In search for the genetic basis of the hph-1 mutation which results in a GTP-CHI-deficient phenotype, it was found that hepatic GTP-CHI mRNA is expressed at 2, 3 and 4 weeks of age which correlates with the observation that these mice show an increase of GTP-CHI activity with age and are hyperphenylalaninemic only until 12 days of age. Though losing this phenotype with age, these animals retain disturbed phenylalanine metabolism. Since no mutation could be found so far in the GTP-CHI gene, it was speculated from these observations that the hph-1 mutation affects GTP-CHI regulation [136] . Patterns of H 4 -biopterin levels and biosynthetic activities were also studied in healthy mice during growth and aging [137] . In all tissues tested, H 4 -biopterin levels and biosynthetic activities strongly increased until about 15 weeks of age, remained almost constant until the age of 50 weeks and then slightly but constantly decreased [137] . In the zebrafish Danio rerio, H 4 -biopterin and its three biosynthetic enzymes GTP-CHI, PTPS and SR are found 24 hours postfertilization and at 48 hours postfertilization, sepiapterin formation branches off H 4 -biopterin biosynthesis by a not yet characterized reaction and gives rise to xanthophore pigments [138] . It was proposed that H 4 -biopterin is required from an early developmental stage on for neurotransmitter synthesis in neurons and for providing tyrosine as a source for melanin biosynthesis in the melanophores [138] . More recently, zebra fish GTP-CHI was cloned and its expression was measured by in situ hybridisation. These experiments confirmed that during the first 72 hours postfertilization, GTP-CHI is expressed in neural crest cells that migrate and differentiate, in melanoblasts as well as in xanthophores. After this time, a dramatic drop in GTP-CHI expression was observed but sepiapterin further accumulated as a pigment in xanthophores (Pelletier, I, Bally-Cuif, L, Boyle, P, Ziegler, I, The pteridine pathway during the development of the zebrafish Danio rerio and its control by GTP cyclohydrolase I, 12 th International Symposium of Chemistry and Biology of Pteridines and Folates, Bethesda, USA, June [17] [18] [19] [20] [21] [22] 2001 ). This suggests that sepiapterin stems from a pathway alternative to H 4 -biopterin de novo synthesis which was thought to provide the precursors for sepiapterin [138] .
In Leishmania, differentiation of the non-infective procyclic promastigotes to the highly infective metacyclic form which takes place in the sand fly is controlled by intracellular H 4 -biopterin levels [125] . These decline during normal development and it was shown that the lower the H 4 -biopterin levels were the higher was the rate of metacyclogenesis and vice versa. In line with this, knock-out of PTR1 (see above) caused hypervirulence in BALB/c mice which was characterized by increased lesion formation and parasite numbers. It was hypothesized that PTR1 limits pathogenesis in the mammalian host in order to ensure parasite transmission due to better survival of the host [125] . The biochemical mechanism by which the drop of intracellular H 4 -biopterin levels can trigger differentiation awaits further investigation.
Another regulation of H 4 -biopterin biosynthesis was observed in the myxomycete Physarum polycephalum. During the naturally synchronous cell cycle of this organism, pteridine biosynthesis is almost unchanged [112, 15] whereas a dramatic down-regulation is observed in differentiation into spherules [15] and sporangia [117] . Both of these processes are induced by starvation and the latter is finally induced by a daylight pulse. During the 5-day starvation period necessary to achieve the sporulation competent state, NOS expression is strongly increased. NO/cGMP signalling was found to be essential for light-induced expression of lig1, a sporulation-specific transcript, and sporulation itself which is characterized by condensation of the macroplasmodium and final development of melaninpigmented sporangia [117] . Though down-regulation of GTP-CHI and up-regulation of NOS seem to be a contradiction, this behaviour can be explained by the fact that growth arrest is a prerequisite for differentiation. Thus, supply with folate has to be restricted and this is obviously paramount to supply with H 4 -biopterin. It also should be emphasized that even at a late stage of starvation, Physarum still has intracellular H 4 -biopterin exceeding those of cytokine-stimulated mammalian cells suggesting that cofactor supply for NOS and phenylalanine hydroxylase is sufficient. Re-feeding the differentiating macroplasmodium at any stage with glucose inhibits sporulation, induces GTP-CHI expression and down-regulates NOS expression [117] . In several of these conditions, DHPR is regulated coordinately with GTP-CHI (C. Wild, G. Golderer, P. Gröbner, G. Werner-Felmayer, E.R. Werner, submitted). Further work will clarify more details concerning the signalling cascade responsible for light-induced sporulation and how glucose level-dependent up-and down-regulation of GTP-CHI and DHPR are accomplished. Obviously, Physarum has no means to separately regulate H 4 -biopterin and folate de novo biosynthesis but the controlled regulation of DHPR suggests that at least aromatic amino acid hydroxylation could be reduced by such a mechanism. NOS, on the other hand, would not require functional DHPR but high enough H 4 -biopterin levels during translation of newly transcribed NOS mRNA.
Involvement of H 4 -biopterin/NO in sporulation also occurs in fungi, as was shown for the zygomycete Phycomyces blakesleeanus. In this organism, light-induced formation of macrosporangiophores is inhibited by inhibiting GTP-CHI and NO release upon light was demonstrated. Furthermore, sodium nitroprusside, an NO donor, could induce formation of macrosporangiophores without light and NOS inhibitors significantly reduced formation of macrosporangiophores [118] . Taken together, the results for Physarum and Phycomyces suggest that H 4 -biopterindependent NO-signalling is a crucial step in light-induced sporulation and it will be interesting to identify the switches that regulate this process.
FINAL REMARKS
Though having been a field of intense research for several decades, there are still many unresolved questions concerning regulation of H 4 -biopterin biosynthesis and biological roles of H 4 -biopterin. Certainly, many of them can be explained by its cofactor activity or its reduction/oxidation chemistry but there may also be not yet defined mechanisms by which H 4 -biopterin could function. Particularly, studying differentiation processes in various biological models could provide important clues for a better understanding of how the decision between growth and differentiation is regulated. These could potentially apply also to more complex systems like development and differentiation in mammals. With respect to regulation of H 4 -biopterin biosynthesis, further studies concerning the promoters of the biosynthetic enzymes, a possible role for alternative splicing and species-specific differences of gene organization are required. To mention just one example, it was shown that the gene encoding Drosophila DHPR has two alternative promoters [138] . Similarly, also Drosophila GTP-CHI is known to use two transcription start sites [32] . So far, studies are lacking whether these transcripts are differentially expressed during development or in a tissuespecific way, how their expression is controlled and whether alternative promoters for these genes can also be found in other species.
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